mRNA |
carboplatin:etoposide (40:17 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.066 |
0.04 |
mRNA |
tigecycline |
CTRPv2 |
pan-cancer |
AAC |
0.12 |
0.04 |
mRNA |
alisertib:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.078 |
0.04 |
mRNA |
dabrafenib |
CTRPv2 |
pan-cancer |
AAC |
-0.1 |
0.04 |
mRNA |
hyperforin |
CTRPv2 |
pan-cancer |
AAC |
-0.086 |
0.04 |
mRNA |
nintedanib |
CTRPv2 |
pan-cancer |
AAC |
-0.086 |
0.04 |
mRNA |
Parthenolide |
CTRPv2 |
pan-cancer |
AAC |
0.084 |
0.04 |
mRNA |
BRD-K34222889 |
CTRPv2 |
pan-cancer |
AAC |
0.069 |
0.04 |
mRNA |
968 |
CTRPv2 |
pan-cancer |
AAC |
-0.16 |
0.04 |
mRNA |
decitabine |
CTRPv2 |
pan-cancer |
AAC |
0.061 |
0.04 |